Notices to Licensee. Unless otherwise specified in this Agreement, reports, notices and other communications from DFCI to Licensee as provided hereunder must be sent to: GenPath Pharmaceuticals, Inc. c/o ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ ▇▇▇▇ and ▇▇▇▇ LLP ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ or other individuals or addresses as Licensee subsequently furnish by written notice to DFCI.
Appears in 2 contracts
Sources: Exclusive License Agreement, Exclusive License Agreement (Aveo Pharmaceuticals Inc)